Device Trial Radar · NCT01713062
Longterm-Evaluation of Vitelene® Against Standard
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
400
Actual
Start
Jan 2012
Primary completion
Apr 2027
Study completion Jun 2030
Sponsor
- Lead sponsor
- Aesculap AGNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 24, 2012
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this randomised prospective multicenter longterm study is to evaluate the survival rate of the implant, wear and periprosthetic osteolysis of highly cross-linked polyethylene with and without addition of Vitamin E (UHMWPE-XE vs. UHMWPE-X) in Total Hip Arthroplasty.
Conditions
- Osteoarthritis, Hip
- Arthritis
Interventions
ViteleneDevice
THA
XLPEDevice
THA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Analysis and measurement of oxidation index of the Polyethylene Inlay after RevisionTime frame: Oxidation index is assessed in case of loosening and revision within 15 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Fachklinik für Orthopädie, Unfallchirurgie, WirbelsäulenchirurgieMarienhaus Klinikum St. Josef
Bendorf, Germany
Klinik für Orthopädie und Unfallchirurgie
Bochum, Germany
Klinik und Poliklinik für Orthopädie
Halle, Germany
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.